Background Bempegaldesleukin, NKTR-214, and nivolumab, Opdivo, was granted breakthrough deisgnation by the FDA for the first line treatment of patients with previously untreated unresectable or metastatic melanoma. Bempegaldesleukin, NKTR-214, is…
Background Pancreatic cancer is one of the most challenging types of cancer to treat, but new therapy using the body’s own immune system is providing new hope. Researchers at Baylor…
About Non Small Cell Lung Cancer, NSCLC Lung cancer is the leading cause of cancer death globally. Each year 1.76 million people die as a result of the disease; this…
Background - The first standard treatment for advanced ovarian cancer patients is platinum-based chemotherapy. If the patient responds to this chemotherapy, she will continue to receive it to the maximum…
Background - The combination of regorafenib (Stivarga) and nivolumab (Opdivo) will be compared with regorafenib alone in a phase III trial of patients with microsatellite stable (MSS) colorectal (CRC), cancer,…
About Orphan Drug and the "CASPIAN" - The FDA has granted an orphan drug designation to “Durvalumab” (“Imfinzi”) for the treatment of patients with small cell lung cancer, SCLC. Data…
About the approval, the studies and the drug, entrectinib - The first regulatory approval has been granted to entrectinib (Rozlytrek) in Japan for the treatment of adult and pediatric patients…
The study and treatment At the World Congress on Gastrointestinal Cancer, held in Barcelona, Spain, on July 3-6, 2019, updated results from a study of 663 metastatic colorectal cancer patients…
The best management for any patient with cancer is receiving the most innovative cancer drugs in advanced stages of development. There, the hope and chances to live longer go far…
A new drug called Entrectinib for the treatment of children and adults with cancer that has recurred or is resistant to treatment, including brain cancers About Entrectinib - Entectinib is…